SEC Filing Analysis: Elanco Animal Health Inc (ELAN)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The President and CEO, Jeffrey N. Simmons, was awarded a small number of Deferred Stock Units (DSUs) as part of a compensation plan. The transaction is routine and has no material financial impact.
• Market Impact: Neutral. The transaction is too small to influence market sentiment or trading volume.

Company Information

Field	Value
Company	Elanco Animal Health Inc
Ticker Symbol	ELAN
CIK	0001739104
Industry	PHARMACEUTICAL PREPARATIONS [2834]

Insider Information

Field	Value
Name	Simmons Jeffrey N
CIK	0001479079
Title/Position	PRESIDENT, CEO AND DIRECTOR
Relationship	Director, Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-10-17
Transaction Code	A (Grant)
Security Type	Deferred Stock Units
Shares Involved	129.2829
Price Per Share	$21.42
Total Value	$2,769.28
Shares Owned After	18,099.5935
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$2,769.28
% of Market Cap	<0.001%
Shares Transacted	129.2829
% of Shares Outstanding	<0.001%
Post-Transaction Ownership	18,099.5935 shares (0.0036% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The transaction value of approximately $2,800 is negligible for a company with a market capitalization of $10.64 billion.
• Ownership Concentration: The grant results in a minuscule increase in the CEO's already small ownership stake (0.0036% of total shares outstanding), indicating no significant shift in control or alignment.
• Dilution Impact: The issuance of 129.2829 new potential shares has a zero-to-negligible dilutive effect on the 496.8 million shares outstanding.
• Transaction Significance: The transaction is classified as 'Low' significance as its value is far below 0.1% of the market cap and the shares involved are far below 0.1% of the shares outstanding. It is a standard executive compensation event, not a market-moving insider trade.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is a non-discretionary grant of a very small value. It does not signal any new information about the company's prospects and will not be interpreted by the market as a bullish or bearish signal.

Volume & Sentiment

• Expected Volume Impact: None. The transaction is too small to affect trading volume.
• Sentiment Indicator: Neutral. This filing is informational and relates to standard executive compensation practices.

Investment Insights

Positive Market Indicators

• N/A. The transaction is not indicative of positive market sentiment.

Risk Factors

• N/A. The transaction poses no risk factors.

Key Takeaways

1. Routine Compensation: The Form 4 filing reports a standard grant of Deferred Stock Units to the CEO, a common practice for executive compensation.
2. No Market Signal: The transaction is not an open-market purchase or sale and therefore provides no insight into the insider's view of the company's future stock performance.
3. Immaterial Value: With a total value of under $3,000, the transaction is financially insignificant to both the insider and the company, which is valued at over $10 billion.

Additional Context

Transaction Notes

• Special Circumstances: The footnotes indicate the Deferred Stock Units were granted under the 'Executive Deferral and Stock Match Plan' and will settle in cash or stock upon termination of employment or a specified future date.
• Market Environment: The transaction is independent of current market conditions and is part of a pre-established compensation schedule.